Xiuxia Wang

Dr. Xiuxia Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
XTXiaoyu Tian
Xiaoyu Tian
YZYange Zhang
Yange Zhang
JZJinhong Zhang
Jinhong Zhang
YLYan Lu
Yan Lu
XMXinyi Men
Xinyi Men
XWXiuxia Wang
Xiuxia Wang
Tian X, et al. Yonsei Med J. 2021 Apr;62(4):370-373. https://doi.org/10.3349/ymj.2021.62.4.370

12 September 2024 in Clinical Neuropharmacology
Verified
Journal Article
Open access
ZZZhimin Zhao
Zhimin Zhao
YQYun Qian
Yun Qian
YDYasong Du
Yasong Du
HCHong Chen
Hong Chen
JHJie He
Jie He
FJFuyong Bs Jiao
Fuyong Bs Jiao
Objective: This study aimed to explore the efficacy of the clonidine adhesive patch for participants with Tourette syndrome (TS). Methods: This randomized, double-blind, placebo-controlled, multicenter phase IV clinical trial included participants with TS at 20 centers between May 2012 and March 2015. Treatment efficacy at week 8 was the primary outcome. The Clinical Global Impression–Severity scale and Improvement scale were the secondary endpoints. Results: This trial included 488 participants, with 121 participants in the 2.0-mg/wk group, 119 participants in the 1.5-mg/wk group, 126 participants in the 1.0-mg/wk group, and 122 participants in the placebo group. For Yale Global Tic Severity Scale score reduction rate, compared with the placebo group (39.60 ± 25.56), those of the 2.0-mg/wk group (63.21 ± 32.60) and the 1.5-mg/wk group (68.16 ± 25.88) were statistically significantly different (all P < 0.001). For total Yale Global Tic Severity Scale score, compared with the placebo group (17.0 ± 8.03), the score for the 2.0-mg/wk group was 9.9 ± 8.36 (P < 0.001); 1.5-mg/wk group, 9.6 ± 8.03 (P < 0.001); and 1.0-mg/wk group, 10.5 ± 9.28 (P < 0.001). The Clinical Global Impression–Severity scale and Improvement scale scores were statistically significantly different in the 3 clonidine (or experimental) groups compared with the placebo group (all P < 0.001). Conclusions: Larger doses of the clonidine adhesive patch such as 1.5 and 2.0 mg/wk are effective in improving the symptoms and overall function of participants with TS.

10 May 2023 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
SZSiyu Zhao
Siyu Zhao
XZXiaoling Zhang
Xiaoling Zhang
LYLe Yang
Le Yang
YWYan Wang
Yan Wang
SJShanShan Jia
ShanShan Jia
DWDong Wang
Dong Wang

13 August 2022 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
JZJinhong Zhang
Jinhong Zhang
YLYan Lu
Yan Lu
XTXiaoyu Tian
Xiaoyu Tian
XMXinyi Men
Xinyi Men
YZYange Zhang
Yange Zhang
XWXiuxia Wang
Xiuxia Wang
Background: Global developmental delay (GDD) has a heterogeneous clinical profile among patients, accounting for approximately 1%–3% of cases in children. An increasing number of gene defects have been demonstrated to be associated with GDD; up to now, only limited studies have reported developmental disorders driven by WDR45B.Methods: Trio‐whole exome sequencing (Trio‐WES) was performed for the patient and her family. All variants with a minor allele frequency C (p. Arg226Thr)] was identified from the proband. The variant was absent in published databases such as gnomAD and Exome Aggregation Consortium (ExAC). The variant was predicted to be damaging for proteins and classified as VUS according to the ACMG guidelines. We reviewed the literature, and the development delay level in our case was less severe than the other reported cases.Conclusion: We reported another case with a novel homozygous variant of WDR45B and showed the heterogeneity of clinical features.